Side Effects of Vagus Nerve Stimulation: What to Expect

Vagus nerve stimulation works — but it is not side-effect-free. Whether you have a surgically implanted VNS device, use a handheld gammaCore unit, or clip a transcutaneous auricular stimulator to your ear, the electrical current that modulates your vagus nerve also affects neighbouring tissues. Understanding the side-effect profile of each approach helps you distinguish normal adaptation from warning signs that need medical attention.

Implanted VNS: The Most Studied Side-Effect Profile

Implanted vagus nerve stimulators — primarily the LivaNova SenTiva system, FDA-approved for drug-resistant epilepsy since 1997 and treatment-resistant depression since 2005 — have the longest track record. The device wraps a helical electrode around the left cervical vagus nerve and delivers programmed electrical pulses, typically at 1.0 to 2.5 milliamps.

The most common side effect is voice alteration, reported by 30 to 65 percent of patients during stimulation. This occurs because the recurrent laryngeal nerve — a branch of the vagus that controls the vocal cords — sits close to the stimulation site. Patients describe hoarseness, a strained quality, or a “robotic” sound during the 30-second ON periods. Voice changes typically diminish between stimulation cycles and often improve over months as the brain adapts to the stimulation pattern.

Cough during stimulation affects roughly 20 to 45 percent of patients, driven by activation of the superior laryngeal nerve’s cough reflex arc. Throat pain or tingling, difficulty swallowing (dysphagia), and shortness of breath are less common but well-documented. Most of these effects are stimulus-bound — they occur during ON periods and resolve during OFF periods — which distinguishes them from complications requiring intervention.

Surgical complications are relatively uncommon. Wound infection occurs in approximately 3 to 6 percent of cases. Left vocal cord paralysis from direct recurrent laryngeal nerve injury is rare (under 1 percent) but can be permanent. Lead fracture or displacement may require revision surgery. Battery depletion necessitates generator replacement every 5 to 10 years, a simpler procedure than the initial implant since the electrode stays in place.

Cardiac Side Effects: Left Versus Right

Implanted VNS targets the left vagus nerve specifically because of cardiac asymmetry. The right vagus nerve predominantly innervates the sinoatrial (SA) node, which controls heart rate, while the left vagus primarily innervates the atrioventricular (AV) node, which controls electrical conduction between the atria and ventricles. Left-sided stimulation therefore has less chronotropic effect — less risk of dangerous bradycardia — than right-sided stimulation would. However, bradycardia during implantation occurs in roughly 0.1 percent of cases, typically during intraoperative lead testing. Asystole has been reported in extremely rare instances.

Post-implant, clinically significant bradycardia is uncommon with left-sided VNS. Patients with pre-existing cardiac conduction disorders should be carefully evaluated before implantation, and cardiac monitoring during initial programming sessions is standard practice.

Your local vagus nerve experts

Find a vagus nerve practitioner near you

Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.

Or browse by approach

The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.

gammaCore (Cervical Non-Invasive VNS)

The gammaCore Sapphire device delivers electrical stimulation transcutaneously to the cervical vagus nerve. FDA-cleared for migraine (episodic and chronic) and cluster headache, it avoids surgical risks entirely but produces its own side-effect profile.

The most frequently reported effects are local skin irritation or redness at the electrode site, mild neck discomfort during stimulation, and a pulling or tingling sensation in the facial muscles or jaw. The PRESTO trial for episodic migraine and the ACT1/ACT2 trials for cluster headache showed adverse event rates comparable to sham stimulation, suggesting gammaCore’s side-effect profile is mild. Occasional lip drooping or facial muscle twitching during stimulation indicates current spread to the facial nerve and can usually be corrected by repositioning the device.

Because cervical stimulation activates the vagus more proximally than auricular approaches, some users experience transient lightheadedness during the two-minute stimulation cycle. This reflects normal parasympathetic activation and typically resolves within seconds of completing the treatment.

Transcutaneous Auricular VNS (taVNS)

Auricular VNS targets the Arnold branch of the vagus nerve at the cymba conchae or tragus of the ear. This approach has the mildest side-effect profile of any VNS modality because it stimulates a small sensory branch far from the cardiac and laryngeal structures affected by cervical stimulation.

A December 2024 JAMA Network Open randomised trial of taVNS for insomnia — 72 adults treated with 30-minute sessions twice daily for eight weeks — reported skin redness at the electrode site and mild ear discomfort as the primary adverse effects, with no serious adverse events in either the active or sham groups. The Parasym Nuropod, a direct-to-consumer taVNS device using AVNT (auricular vagus nerve transduction) technology, similarly reports a favourable safety profile in its Non-Significant Risk designation from the FDA.

The main risk with taVNS is stimulating the wrong ear location. The earlobe, for example, has no vagal innervation — placing electrodes there produces a sham effect. Stimulating the external auditory canal too deeply could theoretically irritate the tympanic membrane. Proper electrode placement on the cymba conchae, where the auricular branch of the vagus is most concentrated, maximises efficacy while minimising off-target effects.

Contraindications Across All VNS Types

Absolute contraindications for implanted VNS include left cervical vagotomy (no nerve to stimulate) and existing implanted devices that could interact electrically, such as certain cardiac pacemakers — though newer VNS systems are increasingly MRI-conditional and compatible with some cardiac devices. Diathermy (shortwave, microwave, or therapeutic ultrasound) is contraindicated in implanted VNS patients because it can heat the electrode and damage the nerve.

For non-invasive VNS, contraindications are fewer but include active implantable devices near the stimulation site, carotid artery atherosclerosis or stenting (for cervical devices), and pregnancy, where safety data remain limited. People taking anticoagulants should be cautious with cervical devices due to the theoretical risk of carotid sinus stimulation triggering a vasovagal response.

Side Effects That Need Medical Attention

Most VNS side effects are nuisances, not emergencies. However, certain symptoms warrant prompt evaluation. For implanted devices: persistent voice change that does not cycle with stimulation ON/OFF periods may indicate vocal cord paralysis from nerve injury rather than functional stimulation effects. Wound redness, swelling, warmth, or drainage at the surgical site suggests infection. New-onset difficulty breathing unrelated to stimulation timing could indicate lead displacement affecting the phrenic nerve or airway structures. Syncope or near-syncope during stimulation requires urgent device interrogation and possible parameter adjustment.

For non-invasive devices: persistent numbness or weakness in the face, tongue, or neck beyond the stimulation period warrants medical evaluation. Chest pain or palpitations during stimulation should prompt discontinuation and cardiology assessment, particularly in patients with known cardiac disease.

Managing Side Effects: The Ramp-Up Approach

The standard clinical approach to minimising side effects is gradual dose titration. Implanted VNS typically starts at low output current (0.25 mA) and increases by 0.25 mA increments every two to four weeks until therapeutic benefit is achieved or side effects become limiting, usually between 1.0 and 2.5 mA. This gradual ramp-up allows neural adaptation and significantly reduces the severity of voice changes and cough compared to immediate high-intensity stimulation.

For non-invasive devices, users can similarly start with shorter sessions and lower intensity settings before working up to full treatment protocols. The habituation period for most side effects is two to three months, after which the brain’s response to the stimulation pattern typically normalises and nuisance effects diminish substantially.

Understanding side effects is just one part of the VNS picture — your vagus nerve influences everything from seizure control to mood regulation. Get the Vagus Nerve & Me eBook for the complete guide to vagal science, stimulation methods, and what the latest research means for your health.